AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06224257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib
Description: Elevated PI3K activity in T-LGL likely plays an important role in the ability of the pathologic cells to avoid homeostatic apoptosis, since inhibition of this pathway leads to apoptosis in the population of cells harboring the pathologic clone. More importantly, the activity of this pathway may represent a kind of Achilles heel for T-LGL in that PI3K inhibitors alone are quite effective at inducing spontaneous apoptosis in the clonal CTLs after a short incubation.
Study NCT06191640 — intervention group
Intervention type: DRUG
Intervention: Ivacaftor or elexacaftor/tezacaftor/ivacaftor
Description: HEMT's are prescribed at the discretion of the treating physician and is not dictated by the principal investigator of this study.
Study NCT04941560 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04910945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VENUS AIME (RoboCor)
Description: VENUS AIME is a micro-coring device of the skin that can potentially help to reduce visible skin scarring, improve skin laxity and reduce wrinkles.
Study NCT06747065 — intervention group
Intervention type: PROCEDURE
Intervention: Radiotherapy
Description: Radiotherapy post-mastectomy prepectoral implant-based breast reconstruction (IBBR)
Study NCT05438121 — intervention group
Intervention type: DEVICE
Intervention: SeQuent Please Neo
Description: DCB angioplasty will be performed in accordance with the recent recommendations. Specifically, aggressive lesion predilation (balloon-to-artery ratio: 0.8 to 1.2) using either a plain balloon or a scoring balloon will be performed.
Study NCT06376825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyLife: An internet-based self-help program to reduce burnout
Description: MyLife is a internet-based and Acceptance and Commitment Therapy oriented self-help program to reduce burnout. In this study a tailored to teachers version of the program will be used.
Study NCT05095467 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: The abdominal cavity will be filled with paclitaxel 120mg/m2 heated at 43℃ for 1 hour with a hyperthermic circulation machine.
Study NCT05095467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-albumin
Description: albumin paclitaxel D1, D8; S-1: D1-D14
Study NCT05095467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-gimeracil-oteracil potassium
Description: 40mg bid(BSA\<1.5 m2) ，60mg bid(BSA>=1.5 m2); D1-D14, po, bid.
Study NCT05095467 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery+HIPEC
Description: gastrectomy with D2 lymphadenectomy+HIPEC procedure
Study NCT05434468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sustained neutral apophyseal glides
Description: gong mobilization
Study NCT06660342 — intervention group
Intervention type: DRUG
Intervention: Vonoprazan
Description: Oral tablet.
Study NCT06663345 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plan Block (TAPB), Lateral Quadratum Lumborum (QLB-1) Block
Description: Following the acquisition of informed consent prior to surgery, 2 mg of intravenous midazolam will be administered to patients who volunteer. These patients will be monitored in the preoperative preparation room. Bilateral TAP or QLB-1 block will be performed, and this block is routinely applied for postoperative pain in our hospital.
Study NCT06663345 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominis Plan Block (TAPB), Lateral Quadratum Lumborum (QLB-1) Block
Description: Following the acquisition of informed consent prior to surgery, 2 mg of intravenous midazolam will be administered to patients who volunteer. These patients will be monitored in the preoperative preparation room. Bilateral TAP or QLB-1 block will be performed, and this block is routinely applied for postoperative pain in our hospital.
Study NCT06608589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CoMPAS+ MNCDs Program - Quality improvement program targeting the care transitions of patients living with a major neurocognitive disorder and their caregivers
Description: COMPAS+ is a collaborative approach to improving healthcare quality. It brings together around 30 individuals, including healthcare professionals, deciders, and patient partners, to identify improvement goals, develop action plans, and enhance the prevention and management of chronic diseases. In this study, the investigators adapt COMPAS+ to focus on improving care transitions for patients with major neurocognitive disorders (MNCDs) and their caregivers. Through reflective workshops and collaborative problem-solving, this diverse group will identify best practices and create action plans to enhance care quality.
Study NCT05534646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide
Description: Standard of care Apalutamide 240 mg administered orally and daily on Days 1-28 of every 28 day cycle
Study NCT05534646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Standard of care Apalutamide 240 mg administered orally and daily on Days 1-28 of every 28 day cycle
Study NCT05534646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carotuximab
Description: Carotuximab administered intravenously at the following doses:~Cycle 1 Day 1: 3 mg/kg Cycle 1 Day 4: 7 mg/kg Cycle 1 Day 8: 10 mg/kg Cycle 1 Day 15: 10 mg/kg Cycle 1 Day 22: 10 mg/kg Cycle 2 Day 1: 15 mg/kg Cycle 2 Day 15: 15 mg/kg Cycle 3+ Day 1: 15 mg/kg After completion of cycle 2, dosing of carotuximab will continue at a q4 week schedule using the 15 mg/kg dose.
Study NCT06402825 — intervention group
Intervention type: BEHAVIORAL
Intervention: Fit-for-Fertility program
Description: Women in the intervention group had to delay fertility treatments for 6 months and were offered the interdisciplinary lifestyle intervention, which was provided for a maximum of 18 months or until the end of a pregnancy that occurred. The lifestyle intervention consisted of individual meetings with a dietitian and a kinesiologist trained in motivational interviewing, combined with 12 educational group sessions during the first 6 months. Details of the lifestyle intervention are presented in the previously published protocol (Duval et al., 2015).
Study NCT06542653 — intervention group
Intervention type: PROCEDURE
Intervention: PCI
Description: successful percutaneous coronary intervention (PCI) in Coronary chronic total occlusions (CTOs) patients
Study NCT06542653 — intervention group
Intervention type: DRUG
Intervention: OMT
Description: optimal medical therapy (OMT) in CTO patients, such as aspirin 1td, ACEI/ARB 1td, β blocker 1td, statin 1td.
Study NCT06455202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: barzolvolimab
Description: Subcutaneous Administration
Study NCT06455202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo Subcutaneous Administration
Study NCT05954091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OH2 Injection
Description: OH2 injection will be given intratumorally, and Q2W.
Study NCT05556330 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computer guided autogenous cortical shell technique
Description: computer guided autogenous cortical shell technique
Study NCT05556330 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: computer guided autogenous cortical shell technique
Description: computer guided autogenous cortical shell technique
Study NCT06194656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3 Monoclonal antibodies-Dose A
Description: Dose A, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
Study NCT06194656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3 Monoclonal antibodies-Dose B
Description: Dose B, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
Study NCT06194656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3 Monoclonal antibodies-Dose C
Description: Dose C, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
Study NCT06194656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HER3 Monoclonal antibodies-Dose D
Description: The optimal recommended dosage (RP2D) of SIBP-03intravenous, infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
Study NCT06194656 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SIBP-03 solvent without HER3 antibody, intravenous infusion (IV), once every one weeks, 21 days as a cycle.
Study NCT06194656 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cetuximab injection
Description: Medications used for combination therapy, intravenous infusion (IV). Administer once a week.
Study NCT06194656 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Cetuximab injection
Description: Medications used for combination therapy, intravenous infusion (IV). Administer once a week.
Study NCT06072924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Isotonic Endurance Exercise
Description: Pressing tongue against a pressure sensor at the set number of repetitions per session (individualized per participant) 3 times per day
Study NCT06072924 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Exercise
Description: Pressing tongue against pressure sensor at a low threshold (1-15kPa) 30x/day
Study NCT06044571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prescriptive
Description: Prescriptive A diet and exercise prescription individually tailored to each participant's multiple chronic health conditions will provide concrete advice with less autonomy, and will minimize risks of physiologic changes due to weight loss (hypoglycemia, hypotension, muscle loss). Licensed, trained professionals, Registered Dietician Nutritionists (RDNs) and Physical Therapists (PTs), will introduce clinical reasoning, knowledge, and experience, assess biological adaptations to weight loss, modify prescriptions based on changing medical needs, and provide real-time and asynchronous guidance. Registered Dietician Nutritionists (RDNs) and Physical Therapists (PTs)will deliver group and individual, live sessions to the home by telemedicine. Sessions will last 60-min (Registered Dietician Nutritionist: 20 min; Physical Therapist: 40 min).
Study NCT06044571 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prescriptive
Description: Prescriptive A diet and exercise prescription individually tailored to each participant's multiple chronic health conditions will provide concrete advice with less autonomy, and will minimize risks of physiologic changes due to weight loss (hypoglycemia, hypotension, muscle loss). Licensed, trained professionals, Registered Dietician Nutritionists (RDNs) and Physical Therapists (PTs), will introduce clinical reasoning, knowledge, and experience, assess biological adaptations to weight loss, modify prescriptions based on changing medical needs, and provide real-time and asynchronous guidance. Registered Dietician Nutritionists (RDNs) and Physical Therapists (PTs)will deliver group and individual, live sessions to the home by telemedicine. Sessions will last 60-min (Registered Dietician Nutritionist: 20 min; Physical Therapist: 40 min).
Study NCT06044571 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral
Description: Behavioral Health coaches have a bachelor's degree and take a 6-8-week certification program. Behavioral Health coaches will use a structured manual involving evidence-based behavior change techniques (problem-solving, self-regulation, motivation). Group and individual sessions will be via telemedicine.
Study NCT06044571 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: Behavioral Health coaches have a bachelor's degree and take a 6-8-week certification program. Behavioral Health coaches will use a structured manual involving evidence-based behavior change techniques (problem-solving, self-regulation, motivation). Group and individual sessions will be via telemedicine.
Study NCT06681753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: No training will be planned for the Control Group, and their undergraduate education will be included in the study. After the study data is collected and the study is concluded, the control group will be given breastfeeding support training from the intervention group.
Study NCT05826704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Participants will be taking 2 capsule a day for 6 weeks
Study NCT05826704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics
Description: Participants will be taking 2 capsule a day for 6 weeks
Study NCT05956600 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amisulpride 50 MG
Description: Amisulpride 50 mg titrated to dose range of 50 to 1200 mg
Study NCT06443060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Group
Description: Before starting the Prick procedure, the child in the virtual reality group, which is determined by randomisation, will be given a brief information about how the allergy test will be performed and about virtual reality. Before the Prick test (approximately 2 minutes before the Prick test), the child will start to watch a film deemed appropriate by the experts by wearing virtual reality and headphones. After the child starts watching the film, the child will be asked to extend his/her left arm and solutions will be dripped on the forearm and the puncture will be performed with a lancet. The child will continue to watch the film during the whole procedure.
Study NCT06443060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buzzy Application Group
Description: Before starting the prick procedure, the child in the buzzy group, which was determined by randomisation, will be given a brief information about how the allergy test will be performed and the buzzy device. The children in the buzzy experimental group will be connected to the buzzy cold and vibration device at least 8-10 cm above the area to be treated (upper part of the left arm antecubital fossa) 5-10 seconds before starting the procedure and the prick test application will be started.
Study NCT06443060 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Before starting the prick procedure, the children in the control group determined by randomisation will be given routine explanations according to the outpatient clinic procedure before starting the procedure and the prick test will be applied.
Study NCT06676748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzydamine Hydrochloride
Description: The Difflam Forte Anti-Inflammatory Throat Spray (iNova Pharmaceuticals Pte Ltd, Singapore) is an over-the-counter medication indicated for temporary relief of painful mouth and throat conditions. It contains benzydamine hydrochloride (BH) 3 mg/mL, a non-steroidal anti-inflammatory agent (NSAID), and is recommended for adults to spray 2 to 4 times to the affected throat every 1.5 to 3 hours as needed.
Study NCT06302309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Description: The intervention consists of four sessions of a 'managing the mental state' intervention, of which the first and second session will take place in the home-setting of the patient; the two remaining sessions will take place remotely. The sessions include psychoeducation on what anxiety is and how stress and anxiety can influence FOG, identifying how people are allocating attention and engage in specific thought-processes (e.g. worrisome thoughts) during walking, and educating patients about 'managing the mental state' compensation strategies that involve ways to reduce anxiety or stress and will be specifically tailored to the individual patient.
Study NCT06351592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-SOD
Description: Administered by intrathecal (IT) injection
Study NCT06351592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diluent
Description: Administered by IT injection
Study NCT06351592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PB)
Description: Administered by IT injection
Study NCT04719988 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: A total of 9 EDTA (ethylenediaminetetraacetic acid) tubes will be collected at each time point to perform:~PBMC collection: 6 EDTA tubes of 6 ml of peripheral blood mononuclear cell \[PBMC\] will be sent to the central laboratory (Biomonitoring Platform of Besançon, CHRU de Besançon located at Etablissement Français du Sang) at room temperature within 24 hours via an approved carrier for their processing, storage and immunomonitoring analysis. A sending sheet of the samples will be attached to each single sample.~Plasma collection: One 6 ml EDTA tube should be frozen in each investigation center for plasma collection.~Plasma for circulating tumoral DNA (ctDNA) collection: Two 4 ml EDTA tube should be frozen in each investigation center for ctDNA collection.
Study NCT04719988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: A tumor biopsy will be performed at 2 months after enrollment.
Study NCT03277170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast Oral Granules
Description: Montelukast granules, 30 mg, mixed with applesauce
Study NCT03277170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast Oral Granules
Description: Montelukast granules, 30 mg, mixed with applesauce
Study NCT04005209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: The experimental group will receive a ketamine intravenous infusion, initiated at 0.2 mg/kg/hr within the first 12 to 24 hours on an inpatient admission for sickle cell pain crisis, and titrated per hospital policy by the inpatient pain service.
Study NCT04005209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain management
Description: Pain management
Study NCT04005209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain management
Description: Pain management
Study NCT04802876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Spartalizumab (PDR001) 400mg will be given intravenously every 28 days
Study NCT04802876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 300mg will be given intravenously every 28 days
Study NCT05723549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1803-3
Description: Take it once per period
Study NCT05723549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD2002
Description: Take it once per period
Study NCT05723549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCP1904-1
Description: Take it once per period
Study NCT06697678 — intervention group
Intervention type: OTHER
Intervention: No Intervention: Observational Cohort
Description: No intervention
Study NCT06700044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GutMagnific
Description: Participants will take one stick/10\^9 CFU of probiotic dietary supplement GutMagnific per day from gestational week 12 until gestational week 37
Study NCT06700044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take one stick/placebo per day from gestational week 12 until partus.
Study NCT06619639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social-emotional learning curriculum
Description: EMPOWER is a 16-week social-emotional learning curriculum that is integrated into the after-school program context.
Study NCT06627426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR-based patient informed consent
Description: The intervention group will be the on receiving VR-based patient informed consent. One surgeon from the study team will be guiding the patient through their VR model first with demonstration of the technology and the model, afterwards the patient will be enabled to use the VR system by themselves. During the whole process the patient will be able to ask questions. Depending on the planned surgery, the surgical approach as well important anatomical structures will be explained.
Study NCT06630351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Counseling
Description: Participate in MCP-C
Study NCT06630351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Participate in virtual group discussions
Study NCT06630351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Receive reading exercises and workbook materials
Study NCT06630351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies
Study NCT06630351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06406101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Floor
Description: Uninterrupted 2-minute chest compressions on a manikin that has been moved from the bed to the floor in a simulated scenario of out-of-hospital cardiac arrest
Study NCT06406101 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bed
Description: Uninterrupted 2-minute chest compressions on a manikin that is laying on bed in a simulated scenario of out-of-hospital cardiac arrest
Study NCT05903027 — intervention group
Intervention type: DRUG
Intervention: Rimegepant 75 MG Disintegrating Oral Tablet
Description: Patients using Rimegepant 75 mg orally disintegrating tablet to treat acute migraine attacks
Study NCT05567952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nirmatrelvir
Description: Participants will receive 2 tablets of nirmatrelvir every 12 hours